Literature DB >> 8778684

Novel versus conventional antipsychotic drugs.

R C Love1.   

Abstract

Novel antipsychotic agents differ from conventional ones in several key characteristics, including effectiveness, adverse reactions, and receptor-binding profile. Most of the newer agents have an affinity for the serotonin 5HT2 receptor that is at least 10 times greater than that for the dopamine D2 receptor. This increased affinity for the serotonin receptor may be responsible for another distinguishing characteristic of novel antipsychotic agents--decreased frequency of extrapyramidal side effects. These side effects, which include pseudoparkinsonism, acute dystonias, and akathisia, frequently are the reason for noncompliance with conventional drug therapy. The newer drugs are often effective in patients resistant to treatment with conventional agents. They also appear to reduce the negative symptoms of schizophrenia in many patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8778684

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

Review 1.  Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?

Authors:  A Gurevich; V Guller; Y N Berner; S Tal
Journal:  J Nutr Health Aging       Date:  2012       Impact factor: 4.075

2.  Olanzapine and pulmonary embolism, a rare association: a case report.

Authors:  Julian Fz Maempel; Geraldine Darmanin; Kashif Naeem; Mehool Patel
Journal:  Cases J       Date:  2010-01-22

3.  Reemergence of positive symptoms of schizophrenia during the course of treatment with risperidone.

Authors:  P Bajaj; N Nihalani; N Shah; N Desai; V Shinde; N Raut
Journal:  Indian J Psychiatry       Date:  1999-04       Impact factor: 1.759

4.  Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.

Authors:  J V Lucey; S E Libretto
Journal:  Ir J Med Sci       Date:  2003 Oct-Dec       Impact factor: 1.568

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.